Detectable Neuropsychological Differences in Early Preclinical Alzheimer’s Disease: A Meta-Analysis
The development of methods for in vivo detection of cerebral beta amyloid retention and tau accumulation have been increasingly useful in characterizing preclinical Alzheimer’s disease (AD). While the association between these biomarkers and eventual AD has been demonstrated among cognitively intact older adults, the link between biomarkers and neurocognitive ability remains unclear. We conducted a meta-analysis to test the hypothesis that cognitively intact older adults would show statistically discernable differences in neuropsychological performance by amyloid status (amyloid negative = A-, amyloid positive = A+). We secondarily hypothesized a third group characterized by either CSF tau pathology or neurodegeneration, in addition to amyloidosis (A+/N+ or Stage 2), would show lower neuropsychology scores than the amyloid positive group (A+/N- or Stage 1) when compared to the amyloid negative group. Pubmed, PsychINFO, and other sources were searched for relevant articles, yielding 775 total sources. After review for inclusion/exclusion criteria, duplicates, and risk of bias, 61 studies were utilized in the final meta-analysis. Results showed A+ was associated with poorer performance in the domains of global cognitive function, memory, language, visuospatial ability, processing speed, and attention/working memory/executive functions when compared to A-. A+/N+ showed lower performances on memory measures when compared to A+/N- in secondary analyses based on a smaller subset of studies. Results support the notion that neuropsychological measures are sensitive to different stages of preclinical AD among cognitively intact older adults. Further research is needed to determine what constitutes meaningful differences in neuropsychological performance among cognitively intact older adults.
KeywordsCognition Preclinical Alzheimer’s disease Biomarker Meta-analysis
SDH is supported by National Institute on Aging grant K23AG040625, and the American Federation for Aging Research (AFAR). NHS serves as a consultant to Biogen. The funding agencies had no role in this study.
- Ayutyanont, N., Langbaum, J. B., Hendrix, S. B., et al. (2014). The Alzheimer’s Precention initiative composite cognitive test score: Sample size estimates for the evaluation of preclinical Alzheimer’s disease treatments in presenilin 1 E280A mutation carriers. The Journal of Clinical Psychiatry, 75, 652–660.CrossRefPubMedPubMedCentralGoogle Scholar
- Dubois, B., Hampel, H., Feldman, H. H., Scheltens, P., Aisen, P., Andrieu, S., Jack, C. R. (2016). Preclinical Alzheimer’s disease: Definition, natural history, and diagnostic criteria. Alzheimer’s and Dementia, 12, 292–323.Google Scholar
- Hsu, P. J., Shou, H., Benzinger, T., et al. (2014). Amyloid burden in cognitively normal elderly is associated with preferential hippocampal subfield volume loss. Journal of Alzheimer’s Disease, 45(1), 27–33.Google Scholar
- Iturria-Medina, Y., Sotero, R. C., & Toussaint, P. J. (2016). Early role of vascular dysregulation on late-onset Alzheimer’s disease based on multifactorial data-driven analysis. Nature Communications, 7, article number: 11934.Google Scholar
- Jansen, W. J., Ossenkoppele, R., Knol, D. L., Tijms, B. M., Scheltens, P., Verhey, F. R. J., Visser, P. J., & Amyloid Biomarker Study Group. (2015). Prevalence of cerebral amyloid pathology in persons without dementia: A meta-analysis. JAMA, 313(19), 1924–1938.CrossRefPubMedPubMedCentralGoogle Scholar
- Liberati, A., Altman, D. G., Tetzlaff, J., Mulrow, C., Gotzsche, P. C., Ioannidis, J. P. A., Moher, D. (2009). The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. PLOS Medicine, 6, e1000100.Google Scholar
- Lim, Y. Y., Snyder, P. J., Pietrzak, R. H., et al. (2016). Sensitivity of composite scores to amyloid burden in preclinical Alzheimer's disease: Introducing the Z-scores of attention, verbal fluency, and episodic memory for Nondemented older adults composite score. Alzheimer’s & Dementia, 2, 19–26.Google Scholar
- Machulda, M. M., Hagen, C. E., Wiste, H. J., et al. (in press). Practice effects and longitudinal cognitive change in clinically normal older adutls differ by Alzheimer imaging biomarker status. The Clinical Neuropsychologist. doi:10.1080/13854046.2016.1241303.
- Molinuevo, J. L., Ripolles, P., Simó, M., et al. (2014). White matter changes in preclinical Alzheimer's disease: A magnetic resonance imaging-diffusion tensor imaging study on cognitively normal older people with positive amyloid β protein 42 levels. Neurobiology of Aging, 35(12), 2671–2680.CrossRefPubMedGoogle Scholar
- Sperling, R. A., Aisen, P. S., Beckett, L. A., et al. (2011). Toward defining the preclinical stages of Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimer’s & Dementia, 7(3), 280–292.CrossRefGoogle Scholar
- Wirth, M., Madison, C. M., Rabinovici, G. D., et al. (2013a). Alzheimer’s disease neurodegenerative biomarkers are associated with decreased cognitive function but not β-amyloid in cognitively normal older individuals. Neurobiology of Disease, 33(13), 5553–5563.Google Scholar